Use of prednisolone for the treatment of GVHD after nonmyeloablative or myeloablative conditioning. (A) Time to initiation of prednisolone therapy for graft-versus-host disease. (B) Proportion of patients in the nonmyeloablative group (n = 44) and the myeloablative group (n = 52) continuing with prednisolone treatment for the first 12 months after transplantation. Upper panel, related donors; lower panel, unrelated donors.